BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 26213848)

  • 1. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
    Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
    Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
    Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Jo S; Lee YL; Kim S; Lee H; Chung H
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
    Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
    Zhu J; Lallemand-Breitenbach V; de Thé H
    Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
    Giannì M; de Thé H
    Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
    Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
    Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.